Branched-chain alpha-keto acid dehydrogenase complex kinase (BCKDK)

Branched-chain alpha-keto acid dehydrogenase complex kinase (BCKDK) is a mitochondrial enzyme that serves as the primary regulator of branched-chain amino acid (BCAA) catabolism (UniProt, 2024) [3]. It functions by phosphorylating and inactivating the E1-alpha subunit of the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex, which is the rate-limiting step in the breakdown of leucine, isoleucine, and valine (Wikipedia, 2024) [2, 10]. Elevated BCKDK activity leads to the accumulation of BCAAs and branched-chain alpha-keto acids (BCKAs), a metabolic state strongly linked to insulin resistance, type 2 diabetes, obesity, and heart failure (Frontiers, 2022) [6, 9]. In contrast, loss-of-function mutations in the BCKDK gene result in a rare syndrome characterized by low BCAA levels, autism, and epilepsy (MDPI, 2022) [15]. Furthermore, BCKDK is frequently overexpressed in various cancers, where it promotes tumor cell proliferation and survival by activating the mTOR and MAPK signaling pathways (ResearchGate, 2024; PMC, 2018) [5, 18]. Therapeutic strategies focus on small-molecule inhibitors, such as BT2 and 4-phenylbutyrate, which aim to reactivate the BCKDH complex and restore BCAA homeostasis (PMC, 2023) [8, 17]. These inhibitors show promise in treating metabolic disorders and certain malignancies, although potential off-target effects like mitochondrial uncoupling remain a consideration for drug development (ResearchGate, 2026) [12].

Other names

BCKDKBDKBCKDKDBranched-chain ketoacid dehydrogenase kinaseBranched-chain alpha-ketoacid dehydrogenase kinase

Allosteric inhibition of BCKDK to prevent the phosphorylation and inactivation of the BCKDH complex, thereby enhancing the oxidative decarboxylation of branched-chain amino acids and reducing their systemic levels (PMC, 2023; Wikipedia, 2024) [8, 10, 17].